CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017--
Therapeutics, Inc., (NASDAQ:MCRB) today announced that it will
participate in each of the following upcoming healthcare conferences:
Stifel 2017 Healthcare Conference: A corporate overview will be
presented on Tuesday, November 14 at 5:00 p.m. ET in New York, NY.
29th Annual Piper Jaffray Healthcare
Conference: A corporate overview will be presented on Wednesday,
November 29 at 10:30 a.m. ET in New York, NY.
Evercore ISI Biopharma Catalyst/Deep Dive Conference: Members
of the management team will participate in one-on-one meetings on
Thursday, November 30 in Boston, MA.
A live audio webcast of each presentation will be available under the
“Investors and Media” section of Seres’ website. A replay of the
presentation will become available approximately one hour after the
event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
Company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
Therapy and Orphan Drug designations from the U.S. Food and Drug
Administration and is in Phase 3 development for multiply recurrent C.
difficile infection. Seres’ clinical candidate SER-287 has
successfully completed a Phase 1b study in patients with
mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262,
the first ever synthetic microbiome therapeutic candidate, in a Phase 1b
study in patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005134/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications